LIMN

+ Watchlist + Portfolio

Liminatus Pharma, Inc.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.75
52-Week Range: $3.29 – $141.50
Market Cap: $5.24M
P/E (TTM): —
EPS (TTM): -23.50
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 14.50
PEG Ratio: —
Return on Equity: —
Return on Assets: -95.65%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 1.12
Debt/Equity: 4.80
Total Debt: $1.44M
Free Cash Flow: $-10.01M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $3.66M

LIMN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$1.85M	$3.76M	$2.69M	$0.00
Selling, General & Admin	$856.00K	$1.06M	$644.62K	$2.97M
Operating Expenses	$2.71M	$4.82M	$3.33M	$2.97M
Operating Income	-$2.71M	-$4.82M	-$3.33M	-$2.97M
EBITDA	-$2.71M	-$4.81M	-$3.21M	-$9.99M
Pretax Income	-$2.93M	-$4.98M	-$3.55M	-$10.21M
Net Income	-$2.93M	-$4.98M	-$3.55M	-$10.21M
Diluted EPS	-0.11	-0.19	-0.14	-0.43
Diluted Shares	26.01M	26.01M	26.01M	23.75M

LIMN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$5.05M	$434.00K	$56.32K	$337.65K
Receivables	$100.00K	$945.00K	$3.67M	$0.00
Current Assets	$6.84M	$2.24M	$5.28M	$500.57K
Total Assets	$6.84M	$2.24M	$5.41M	$512.79K
Current Liabilities	$17.65M	$18.04M	$24.75M	$10.30M
Total Debt	$16.50M	$16.05M	$19.97M	$1.44M
Total Liabilities	$17.65M	$18.04M	$24.75M	$10.33M
Retained Earnings	-$20.14M	-$25.12M	-$28.67M	-$38.87M
Shareholders' Equity	$0.00	$0.00	-$19.34M	-$9.81M
Working Capital	-$10.81M	-$15.79M	-$19.47M	-$9.80M
Net Debt	$11.45M	$15.62M	$19.92M	$1.10M

LIMN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$869.00K	-$3.35M	-$1.45M	-$9.96M
Capital Expenditure	—	—	—	-$13.11K
Free Cash Flow	-$869.00K	-$3.35M	-$1.45M	-$9.98M
Depreciation & Amortisation	—	—	$0.00	$1.83K
Investing Cash Flow	$0.00	-$819.00K	-$2.85M	-$788.11K
Financing Cash Flow	$5.92M	-$450.00K	$3.92M	$11.03M
Share Repurchases	-$700.00K	$0.00	—	—
Net Change in Cash	$5.05M	-$4.61M	-$378.07K	$281.34K

LIMN Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	—	$0.00	$0.00	$0.00	$0.00
Research & Development	$0.00	—	$0.00	$0.00	$400.00K	$600.00K
Selling, General & Admin	$264.22K	—	$701.17K	$884.21K	$700.90K	$778.91K
Operating Expenses	$264.22K	—	$701.17K	$884.21K	$1.10M	$1.38M
Operating Income	-$264.22K	—	-$701.17K	-$884.21K	-$1.10M	-$1.38M
EBITDA	-$212.01K	$176.32K	-$1.80M	-$8.15M	-$1.10M	-$1.39M
Pretax Income	-$327.53K	—	-$1.82M	-$8.17M	-$1.12M	-$1.41M
Net Income	-$327.53K	—	-$1.82M	-$8.17M	-$1.12M	-$1.41M
Diluted EPS	-0.01	—	-0.07	—	-0.03	-0.03
Diluted Shares	26.01M	—	27.01M	—	36.00M	48.40M

LIMN Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	—	—	$724.50K	$337.65K	$1.91M	$3.02M
Receivables	—	—	$0.00	$0.00	—	—
Current Assets	—	—	$1.20M	$500.57K	$2.78M	$3.39M
Total Assets	$0.00	—	$1.34M	$512.79K	$2.79M	$3.40M
Current Liabilities	$1.06K	—	$2.86M	$10.30M	$2.89M	$3.04M
Total Debt	—	—	$1.44M	$1.44M	$1.44M	$1.44M
Total Liabilities	$1.06K	—	$2.99M	$10.33M	$2.92M	$3.10M
Retained Earnings	-$1.06K	—	-$30.70M	-$38.87M	-$40.00M	-$41.40M
Shareholders' Equity	-$1.06K	—	-$1.65M	-$9.81M	-$132.60K	$300.61K
Working Capital	—	—	-$1.66M	-$9.80M	-$110.88K	$352.04K
Net Debt	—	—	$718.00K	$1.10M	—	—

LIMN Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$159.39K	-$8.82M	-$600.61K	-$386.85K	-$2.02M	-$970.00K
Free Cash Flow	-$159.39K	-$8.82M	-$613.72K	-$386.85K	-$2.02M	-$970.00K
Depreciation & Amortisation	$0.00	$743.00	$542.00	$543.00	$518.00	$468.00
Investing Cash Flow	-$575.00K	-$200.00K	-$13.11K	$0.00	$0.00	$0.00
Financing Cash Flow	$713.00K	$10.32M	$0.00	$0.00	$3.59M	$2.08M
Net Change in Cash	-$21.39K	$1.30M	-$613.72K	-$386.85K	$1.57M	$1.11M

Market Snapshot

About

Liminatus Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases. The company's pipeline includes novel drug candidates targeting unmet medical needs in conditions such as Alzheimer's disease and other cognitive disorders. Liminatus utilizes advanced research platforms to identify and develop small molecule therapeutics with improved efficacy and safety profiles.